1. Infections and Biologic Therapy in Rheumatoid Arthritis
Kevin L. Winthrop, MD, MPH 
Rheumatic Disease Clinics 
Volume 38, Issue 4, Pages (November 2012)
DOI: /j.rdc
Copyright © 2012 Elsevier Inc. Terms and Conditions

2. Fig. 1
Estimated incidences of serious infections in 100 patients per year by treatment and risk profile. Additional risk factors are 1 or 2 of the following: age greater than 60 years, chronic lung disease, chronic renal disease, or high number of treatment failures; 3 risk factors: 2 of these risk factors plus previous serious infections. TNFi, tumor necrosis factor inhibitor.
(From Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011;70:1914–20.)
Rheumatic Disease Clinics  , DOI: ( /j.rdc )
Copyright © 2012 Elsevier Inc. Terms and Conditions